EUVIMEDEUVIMED entdecken
Leitlinie

2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

Adarsh Bhimraj, Yngve Falck-Ytter, Arthur Y Kim, Jonathan Z Li, Lindsey R Baden, Steven Johnson, Robert W Shafer, Shmuel Shoham, Pablo Tebas, Roger Bedimo, Vincent Chi-Chung Cheng, Kara W Chew und 14 weitere

Clinical Infectious Diseases · 16.01.2026 · 81 (Supplement_3) · i6-i12

DOI: 10.1093/cid/ciae435 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 29.10.2024. Verfasst von Adarsh Bhimraj und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, COVID-19, Antibodies, Neutralizing, SARS-CoV-2. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Infectious Diseases Society of America, CDC HHS, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019, developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of the anti–severe acute respiratory syndrome coronavirus 2 neutralizing antibody pemivibart as pre-exposure prophylaxis. The recommendation is based on evidence derived from a systematic review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Information on pemivibart is included in the U.S. Food and Drug Administration Emergency Use Authorization for this agent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-Exposure ProphylaxisCOVID-19Antibodies, NeutralizingSARS-CoV-2COVID-19 Drug TreatmentAntiviral AgentsHumansUnited States

Stichwörter der Autor:innen

COVID-19SARS-CoV-2guidelinepemivibartpre-exposure prophylaxis

Substanzen

Antibodies, NeutralizingAntiviral Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
  • Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
  • Department of Medicine, VA Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Infectious Diseases Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Förderung

  • Infectious Diseases Society of America
  • CDC HHS
  • Centers for Disease Control and Prevention

Zitieren

APA

Bhimraj, A., Falck-Ytter, Y., Kim, A. Y., Li, J. Z., Baden, L. R., Johnson, S., Shafer, R. W., Shoham, S., Tebas, P., Bedimo, R., Cheng, V. C., Chew, K. W., Chiotos, K., Daar, E. S., Dzierba, A. L., Glidden, D. V., Hardy, E. J., Martin, G. S., MacBrayne, C., …, & Gandhi, R. T. (2026). 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clinical Infectious Diseases, 81(Supplement_3), i6-i12. https://doi.org/10.1093/cid/ciae435

Vancouver

Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, et al. 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clinical Infectious Diseases. 2026;81(Supplement_3):i6-i12. doi:10.1093/cid/ciae435

BibTeX
@article{Bhimraj2026,
  author = {Bhimraj, Adarsh and Falck-Ytter, Yngve and Kim, Arthur Y and Li, Jonathan Z and Baden, Lindsey R and Johnson, Steven and Shafer, Robert W and Shoham, Shmuel and Tebas, Pablo and Bedimo, Roger and Cheng, Vincent Chi-Chung and Chew, Kara W and Chiotos, Kathleen and Daar, Eric S and Dzierba, Amy L and Glidden, David V and Hardy, Erica J and Martin, Greg S and MacBrayne, Christine and Nadig, Nandita and Nakamura, Mari M and Shumaker, Amy Hirsch and Tien, Phyllis and Loveless, Jennifer and Morgan, Rebecca L and Gandhi, Rajesh T},
  title = {2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {81},
  number = {Supplement_3},
  pages = {i6--i12},
  doi = {10.1093/cid/ciae435}
}
Kostenlos starten →